| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
CUTTING EDGE |
* Laboratory of Tumour Immunology, Division of Oncology and
Department of Neurosurgery, University Hospital Geneva, Geneva, Switzerland
The number and localization of effector cells to the tumor site are crucial elements for immune rejection of solid tumors. However, for cerebral malignancies, antitumor responses need to be finely tuned to avoid neuropathologic consequences. In this study, we determine factors that regulate CTL localization and tumoricidal function after intracerebral implantation of tumors expressing model Ag. H-2bxd mice implanted with a CW3+ murine glioma lacking H-2Kd molecules necessary to present the CW3170–179 epitope demonstrate cross-priming of H-2Kd-restricted CTL, and moreover, Ag-dependent accumulation of functional H-2Kd/CW3170–179-specific CTL within the tumor bed. This implicates a role for cross-presentation not only in priming, but also in retention of fully differentiated CTL in the tumor stroma at the effector stage of the response. Modulating cross-presentation of Ag may be the key in regulating specific immune responses in the brain: either by augmenting protective responses or by down-modulating destructive autoimmune reactions.
This article has been cited by other articles:
|
|
 |
|
  N. Melzer, S. G. Meuth, and H. Wiendl CD8+ T cells and neuronal damage: direct and collateral mechanisms of cytotoxicity and impaired electrical excitability FASEB J, November 1, 2009; 23(11): 3659 - 3673. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. L. Thomas, M. Kim, N. A. Bowerman, S. Narayanan, D. M. Kranz, H. Schreiber, and E. J. Roy Recurrence of Intracranial Tumors following Adoptive T Cell Therapy Can Be Prevented by Direct and Indirect Killing Aided by High Levels of Tumor Antigen Cross-Presented on Stromal Cells J. Immunol., August 1, 2009; 183(3): 1828 - 1837. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. M. Grauer, J. W. Molling, E. Bennink, L. W. J. Toonen, R. P. M. Sutmuller, S. Nierkens, and G. J. Adema TLR Ligands in the Local Treatment of Established Intracerebral Murine Gliomas J. Immunol., November 15, 2008; 181(10): 6720 - 6729. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Masson, T. Calzascia, W. Di Berardino-Besson, N. de Tribolet, P.-Y. Dietrich, and P. R. Walker Brain Microenvironment Promotes the Final Functional Maturation of Tumor-Specific Effector CD8+ T Cells J. Immunol., July 15, 2007; 179(2): 845 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. F. Hussain, D. Yang, D. Suki, K. Aldape, E. Grimm, and A. B. Heimberger The role of human glioma-infiltrating microglia/macrophages in mediating antitumor immune responses Neuro-oncol, July 1, 2006; 8(3): 261 - 279. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Preynat-Seauve, P. Schuler, E. Contassot, F. Beermann, B. Huard, and L. E. French Tumor-Infiltrating Dendritic Cells Are Potent Antigen-Presenting Cells Able to Activate T Cells and Mediate Tumor Rejection J. Immunol., January 1, 2006; 176(1): 61 - 67. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Friese and L. Fugger Autoreactive CD8+ T cells in multiple sclerosis: a new target for therapy? Brain, August 1, 2005; 128(8): 1747 - 1763. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Okada, T. Tsugawa, H. Sato, N. Kuwashima, A. Gambotto, K. Okada, J. E. Dusak, W. K. Fellows-Mayle, G. D. Papworth, S. C. Watkins, et al. Delivery of Interferon-{alpha} Transfected Dendritic Cells into Central Nervous System Tumors Enhances the Antitumor Efficacy of Peripheral Peptide-Based Vaccines Cancer Res., August 15, 2004; 64(16): 5830 - 5838. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
